GLP-1s, Pregnancy, and Breastfeeding: What the Label Actually Says

Pregnancy planning and breastfeeding require advice for the exact medicine and formulation. Wegovy and Zepbound do not have identical labeling, and low drug transfer into milk does not establish that a medicine is safe for every nursing parent or infant.

Plan pregnancy with the prescriber

For weight-management treatment, Wegovy's label instructs patients to stop at least two months before a planned pregnancy. Zepbound's U.S. label instructs discontinuation when pregnancy is recognized; it does not specify the same two-month preconception interval. Discuss a stopping plan before trying to conceive rather than applying semaglutide's interval to tirzepatide.³⁴

Weight loss is not recommended during pregnancy. The labels describe potential fetal harm and insufficient human pregnancy data. If you become pregnant while using either medicine, contact your prescribing and obstetric teams promptly. Both products have pregnancy exposure registries.³⁴ A review of pregnancy evidence does not establish safety or replace product-specific instructions.²

Zepbound can reduce the effectiveness of oral hormonal contraception. Its label advises a non-oral method or an added barrier method for four weeks after starting and four weeks after each dose escalation.⁴ Review other medication interactions with the clinician as part of the plan.

Wegovy tablets and injection have different lactation guidance

Wegovy tablets contain the absorption enhancer SNAC. Because SNAC or its metabolites enter milk and may accumulate in infants, breastfeeding is not recommended during tablet treatment. The injection lacks SNAC, but its label still describes gaps in human-milk, infant-effect and milk-production data and calls for weighing breastfeeding benefits, maternal need and potential infant risks.³ That distinction is not permission to switch formulations or start an injection without clinical assessment.

What milk-transfer studies can tell us

Zepbound's label describes a single 5 mg dose in 11 lactating adults. Tirzepatide was undetectable in 164 of 171 samples; the amount detected in the others totaled less than 0.02% of the maternal dose over 28 days. The label states that effects on breastfed infants and milk production are unknown.⁴ A single-dose transfer study cannot establish the safety of continuing weekly treatment.

A separate 2024 study found no detectable semaglutide in milk samples from eight women, collected at 0, 12 and 24 hours after administration. Its authors identified unresolved questions about long-term infant outcomes, maternal nutrition and milk nutrient content.¹ Small transfer studies should inform a clinical discussion without becoming a blanket reassurance.

Bring the exact product to the appointment

Tell your clinician the medicine, formulation, reason for treatment, pregnancy plans and feeding circumstances. Ask how stopping treatment would affect any other condition being managed. Our eligibility guide explains why a weight-management threshold alone is not a prescribing decision; the provider checklist helps you ask about access to follow-up care.

This is editorial information, not medical advice. Pregnancy and breastfeeding decisions involving any medication should be made with your OB/GYN or prescribing clinician.